{"id":111984,"date":"2025-07-18T17:14:47","date_gmt":"2025-07-18T08:14:47","guid":{"rendered":"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/"},"modified":"2026-07-12T21:09:27","modified_gmt":"2026-07-12T12:09:27","slug":"fragile-x-syndrome-guide","status":"publish","type":"post","link":"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en","title":{"rendered":"Fragile X Syndrome: Causes, Symptoms, Diagnosis, and Support Systems Explained"},"content":{"rendered":"\n<p><strong>Here is the short answer first. Fragile X syndrome is a genetic condition caused by an abnormal expansion of a three-letter DNA sequence called a CGG repeat within the FMR1 gene on the X chromosome, and it is one of the most common inherited causes of intellectual disability.<\/strong> Males tend to be more severely affected than females, and autism spectrum disorder (ASD) frequently occurs alongside it.<\/p>\n\n\n\n<p>Many people wonder, &#8220;Can fragile X syndrome be detected during pregnancy?&#8221; or &#8220;If I turn out to be a carrier, how will it affect my next child?&#8221; and feel uneasy because the diagnosis and the genetics behind it are hard to follow. This article walks through the genetic change that causes fragile X syndrome, its symptoms, how it is inherited, what can happen to premutation carriers (both women and men), how it relates to <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a>, the path to a definitive diagnosis, and public medical-expense assistance programs \u2014 all based on information from Japan&#8217;s Center for Intractable Disease Information and other public and academic sources.<\/p>\n\n\n\n<div class=\"info-box\" style=\"margin:1.5em 0;padding:1.2em 1.4em;background:#f3f8ff;border-left:5px solid #5b9bd5;border-radius:8px;\">\n<p style=\"font-weight:bold;margin-bottom:0.6em;\">\ud83d\udca1 What you&#8217;ll learn in this article<\/p>\n<ul style=\"margin:0;padding-left:1.2em;\">\n<li>How fragile X syndrome arises from CGG repeat expansion in the FMR1 gene<\/li>\n<li>How CGG repeat counts are classified \u2014 normal, premutation (including the gray zone), and full mutation<\/li>\n<li>Why symptom severity differs between males and females (X-linkage and X-inactivation)<\/li>\n<li>What can happen to female and male premutation carriers (FXPOI and FXTAS)<\/li>\n<li>What <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> can and cannot tell you, and the path to a definitive diagnosis<\/li>\n<li>Treatment and support options, plus medical-expense assistance programs<\/li>\n<\/ul>\n<\/div>\n\n\n\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">\u76ee\u6b21<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#1_What_Is_Fragile_X_Syndrome_Its_Caused_by_CGG_Repeat_Expansion_in_the_FMR1_Gene\" >1. What Is Fragile X Syndrome? It&#8217;s Caused by CGG Repeat Expansion in the FMR1 Gene<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#2_The_Underlying_Genetic_Change_%E2%80%94_CGG_Repeat_Expansion_and_Methylation\" >2. The Underlying Genetic Change \u2014 CGG Repeat Expansion and Methylation<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#1_Classification_by_CGG_repeat_count\" >(1) Classification by CGG repeat count<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#2_Loss_of_FMRP_through_methylation\" >(2) Loss of FMRP through methylation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#3_%E2%80%9CAnticipation%E2%80%9D_%E2%80%94_repeats_that_grow_across_generations\" >(3) &#8220;Anticipation&#8221; \u2014 repeats that grow across generations<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#3_Symptoms_%E2%80%94_Intellectual_Disability_Autism-like_Traits_and_Physical_Features\" >3. Symptoms \u2014 Intellectual Disability, Autism-like Traits, and Physical Features<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#4_Inheritance_Pattern_%E2%80%94_X-linked_Dominant_with_Different_Transmission_Risks_from_Mothers_and_Fathers\" >4. Inheritance Pattern \u2014 X-linked Dominant, with Different Transmission Risks from Mothers and Fathers<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#When_the_mother_carries_a_premutation\" >When the mother carries a premutation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#When_the_father_carries_a_premutation\" >When the father carries a premutation<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#5_What_Can_Happen_to_Female_and_Male_Premutation_Carriers_%E2%80%94_FXPOI_and_FXTAS\" >5. What Can Happen to Female and Male Premutation Carriers \u2014 FXPOI and FXTAS<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#FXPOI_primary_ovarian_insufficiency_in_premutation-carrying_women\" >FXPOI (primary ovarian insufficiency in premutation-carrying women)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#FXTAS_tremorataxia_syndrome_mainly_in_premutation-carrying_men\" >FXTAS (tremor\/ataxia syndrome, mainly in premutation-carrying men)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#6_Diagnosis_%E2%80%94_Confirmed_Through_FMR1_Genetic_Testing\" >6. Diagnosis \u2014 Confirmed Through FMR1 Genetic Testing<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#The_diagnostic_path_after_birth\" >The diagnostic path after birth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#Diagnosis_before_birth_prenatal_diagnosis\" >Diagnosis before birth (prenatal diagnosis)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#7_Can_NIPT_Detect_Fragile_X_Syndrome\" >7. Can NIPT Detect Fragile X Syndrome?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#8_Treatment_and_Support_%E2%80%94_Managing_Symptoms_with_a_Multidisciplinary_Team\" >8. Treatment and Support \u2014 Managing Symptoms with a Multidisciplinary Team<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#9_Medical-Expense_Assistance_Programs_and_Where_to_Seek_Support\" >9. Medical-Expense Assistance Programs and Where to Seek Support<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#Summary\" >Summary<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#Frequently_Asked_Questions\" >Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#Can_NIPT_detect_fragile_X_syndrome\" >Can NIPT detect fragile X syndrome?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#How_does_the_CGG_repeat_count_relate_to_the_disease\" >How does the CGG repeat count relate to the disease?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#What_effects_can_female_carriers_experience\" >What effects can female carriers experience?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#Will_it_be_passed_on_to_my_next_child\" >Will it be passed on to my next child?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#Is_it_related_to_autism_spectrum_disorder\" >Is it related to autism spectrum disorder?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\/#Are_there_medical-expense_assistance_programs\" >Are there medical-expense assistance programs?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_What_Is_Fragile_X_Syndrome_Its_Caused_by_CGG_Repeat_Expansion_in_the_FMR1_Gene\"><\/span><strong>1. What Is Fragile X Syndrome? It&#8217;s Caused by CGG Repeat Expansion in the FMR1 Gene<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Fragile X syndrome (FXS) is a &#8220;triplet repeat disorder&#8221;: a three-base CGG sequence inside the FMR1 gene, located near the tip of the long arm of the X chromosome (Xq27.3), lengthens over generations, and the condition develops once the repeat exceeds 200 copies.<\/strong> Once the CGG repeat expands this far, the DNA becomes methylated, transcription of the FMR1 gene shuts down, and a protein called FMRP \u2014 essential for neural development \u2014 stops being produced. This is what leads to intellectual disability and other developmental features.<\/p>\n\n\n\n<p>According to Japan&#8217;s <a href=\"https:\/\/www.nanbyou.or.jp\/entry\/4613\" target=\"_blank\" rel=\"noopener\">Center for Intractable Disease Information (Designated Intractable Disease 206)<\/a>, a CGG repeat count of 50 or fewer is considered normal, 50\u2013200 falls into the fragile X-associated disorders range (discussed below), and more than 200 causes fragile X syndrome itself. On frequency, the <a href=\"https:\/\/www.msdmanuals.com\/professional\/pediatrics\/chromosome-and-gene-abnormalities\/fragile-x-syndrome\" target=\"_blank\" rel=\"noopener\">MSD Manual Professional Version<\/a> reports roughly 1 in 4,000 males and 1 in 8,000 females, making it one of the most common identifiable causes of inherited intellectual disability.<\/p>\n\n\n\n<p>In Japan, fragile X syndrome is recognized as Designated Intractable Disease 206 and is eligible for public medical-expense assistance. The number of people actually certified for that assistance (fewer than 100) reflects only those who meet severity and age criteria \u2014 it is not the same as the true number of people living with the condition. Noticing developmental delays in infancy and moving early toward genetic testing makes an important difference.<\/p>\n\n\n\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_The_Underlying_Genetic_Change_%E2%80%94_CGG_Repeat_Expansion_and_Methylation\"><\/span><strong>2. The Underlying Genetic Change \u2014 CGG Repeat Expansion and Methylation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>At its core, fragile X syndrome is a &#8220;dynamic mutation&#8221;: the CGG repeat in the FMR1 gene grows longer with each generation.<\/strong> Because the name and the future risk both change depending on the repeat count, it helps to start with how the categories are defined.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_Classification_by_CGG_repeat_count\"><\/span><strong>(1) Classification by CGG repeat count<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-table-block\"><table><thead><tr><th>Category<\/th><th>Approximate CGG repeat count<\/th><th>Characteristics<\/th><\/tr><\/thead><tbody><tr><td>Normal<\/td><td>50 or fewer<\/td><td>Essentially no risk of expanding in the next generation<\/td><\/tr><tr><td>Premutation (fragile X-associated disorders range)<\/td><td>50\u2013200<\/td><td>Usually no symptoms in the carrier, but the repeat can expand to a full mutation in the next generation. Carriers face the FXPOI and FXTAS risks described below<\/td><\/tr><tr><td>Full mutation (fragile X syndrome)<\/td><td>Over 200<\/td><td>Methylation silences FMR1 transcription; loss of FMRP produces symptoms<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>These three categories come from the <a href=\"https:\/\/www.nanbyou.or.jp\/entry\/4613\" target=\"_blank\" rel=\"noopener\">Center for Intractable Disease Information<\/a>. Academically, a more detailed four-tier breakdown is also used \u2014 normal (roughly 5\u201340), gray zone (roughly 41\u201358), premutation (roughly 59\u2013200), and full mutation (over 200) \u2014 and the exact cut-offs vary somewhat between sources (<a href=\"https:\/\/grj.umin.jp\/grj\/fmr1.htm\" target=\"_blank\" rel=\"noopener\">GeneReviews Japan<\/a>).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_Loss_of_FMRP_through_methylation\"><\/span><strong>(2) Loss of FMRP through methylation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Once the CGG repeat exceeds 200 copies, DNA methylation occurs at that site and effectively switches the FMR1 gene &#8220;off.&#8221; As a result, a protein called FMRP \u2014 which plays a role in forming and fine-tuning synapses in nerve cells \u2014 is no longer produced, leading to a wide range of features that can include intellectual disability and autism-like behavior.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_%E2%80%9CAnticipation%E2%80%9D_%E2%80%94_repeats_that_grow_across_generations\"><\/span><strong>(3) &#8220;Anticipation&#8221; \u2014 repeats that grow across generations<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Premutation-length CGG repeats tend to become unstable when passed down, especially from mother to child, and the repeat count often grows larger with each generation. This phenomenon is called &#8220;anticipation,&#8221; and it is thought to be one reason why children of a premutation-carrying parent can show more severe symptoms than their grandparents&#8217; generation did.<\/p>\n\n\n\n<p>For more on how small chromosomal and genetic changes like this one relate to intellectual disability in general, see our article on <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/nipt-intellectual-disability-statistics-probability\/\">NIPT and intellectual disability: probability, accuracy, and limitations explained with numbers<\/a> (Japanese).<\/p>\n\n\n\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_Symptoms_%E2%80%94_Intellectual_Disability_Autism-like_Traits_and_Physical_Features\"><\/span><strong>3. Symptoms \u2014 Intellectual Disability, Autism-like Traits, and Physical Features<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Fragile X syndrome symptoms show up in three areas \u2014 intellectual development, behavior, and physical features \u2014 and males tend to be more severely affected than females.<\/strong> The table below summarizes the reported characteristics.<\/p>\n\n\n\n<figure class=\"wp-table-block\"><table><thead><tr><th>Area<\/th><th>Main features<\/th><th>Reported frequency \/ severity<\/th><\/tr><\/thead><tbody><tr><td>Intellectual development<\/td><td>Delayed language development, difficulty with abstract thinking and planning<\/td><td>Per the MSD Manual, mild to moderate intellectual disability; tends to be more severe in males<\/td><\/tr><tr><td>Behavior<\/td><td>Avoiding eye contact, social anxiety, repetitive\/restricted interests, hyperactivity, sensory sensitivity<\/td><td>A relatively high proportion of males are reported to meet diagnostic criteria for autism spectrum disorder<\/td><\/tr><tr><td>Physical features<\/td><td>A long, narrow face, prominent large ears, and \u2014 in males after puberty \u2014 enlarged testes (macroorchidism)<\/td><td>Listed as characteristic findings by the <a href=\"https:\/\/www.nanbyou.or.jp\/entry\/4613\" target=\"_blank\" rel=\"noopener\">Center for Intractable Disease Information<\/a><\/td><\/tr><tr><td>Neurological \/ physical comorbidities<\/td><td>Joint hyperextensibility, flat feet, mitral valve prolapse, strabismus, epilepsy<\/td><td>According to the <a href=\"https:\/\/www.shouman.jp\/disease\/html\/detail\/11_10_027.html\" target=\"_blank\" rel=\"noopener\">Center for Pediatric Chronic Disease Information<\/a>, epilepsy occurs in 15\u201320% of cases<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Because women have two X chromosomes, the second, unaffected copy of FMR1 can compensate to some degree, so symptoms are more often mild to moderate. This individual variability is thought to be related to skewing in X-chromosome inactivation (lyonization).<\/p>\n\n\n\n<p>If you&#8217;re wondering about the link to autism spectrum disorder, see our article on <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/nipt-autism-developmental-disorders-detection\/\">whether NIPT can detect developmental disorders and autism, and how testing limits relate to genetics<\/a> (Japanese).<\/p>\n\n\n\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_Inheritance_Pattern_%E2%80%94_X-linked_Dominant_with_Different_Transmission_Risks_from_Mothers_and_Fathers\"><\/span><strong>4. Inheritance Pattern \u2014 X-linked Dominant, with Different Transmission Risks from Mothers and Fathers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Fragile X syndrome follows an X-linked dominant inheritance pattern, but whether a premutation expands into a full mutation in the next generation depends heavily on whether it was inherited from the mother or the father.<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"When_the_mother_carries_a_premutation\"><\/span><strong>When the mother carries a premutation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A premutation tends to become unstable when passed from mother to child, and the larger the repeat count, the higher the risk it will expand into a full mutation. According to <a href=\"https:\/\/grj.umin.jp\/grj\/fmr1.htm\" target=\"_blank\" rel=\"noopener\">GeneReviews Japan<\/a>, when a mother&#8217;s repeat count is 56\u201359, the risk that a son will develop fragile X syndrome is approximately 7%, and for a daughter approximately 3.5% \u2014 and this risk tends to rise further as the mother&#8217;s repeat count increases.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"When_the_father_carries_a_premutation\"><\/span><strong>When the father carries a premutation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A father&#8217;s premutation is never passed to sons (who inherit his Y chromosome, not his X). It is always passed to daughters, who then become carriers themselves. Premutations inherited from the father are known to be less likely to expand into a full mutation than those inherited from the mother \u2014 but once a daughter has children of her own, the maternal transmission risk described above applies to her.<\/p>\n\n\n\n<p>In genetic counseling, one of the most common questions we hear is, &#8220;Now that I know I&#8217;m a carrier, how might this affect my siblings or my future children?&#8221; The answer depends on the repeat count within the family and the route of transmission, so it needs to be worked through step by step with a clinical geneticist or certified genetic counselor.<\/p>\n\n\n\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_What_Can_Happen_to_Female_and_Male_Premutation_Carriers_%E2%80%94_FXPOI_and_FXTAS\"><\/span><strong>5. What Can Happen to Female and Male Premutation Carriers \u2014 FXPOI and FXTAS<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Premutation carriers usually don&#8217;t develop intellectual disability or other core symptoms of fragile X syndrome themselves. However, in midlife and beyond, women can develop FXPOI (fragile X-associated primary ovarian insufficiency) and men can develop FXTAS (fragile X-associated tremor\/ataxia syndrome) \u2014 conditions classified together as fragile X-associated disorders (Designated Intractable Disease 205).<\/strong> Being a carrier is rarely the end of the story \u2014 the genetics run deeper than that.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FXPOI_primary_ovarian_insufficiency_in_premutation-carrying_women\"><\/span><strong>FXPOI (primary ovarian insufficiency in premutation-carrying women)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>FXPOI is defined as the cessation of menstruation before age 40 in a woman who carries a premutation. According to <a href=\"https:\/\/grj.umin.jp\/grj\/fmr1.htm\" target=\"_blank\" rel=\"noopener\">GeneReviews Japan<\/a>, while the risk in the general population is about 1%, it rises to roughly 21% (estimated range 15\u201327%) among premutation carriers, with rare cases reported as early as age 11. It can present as irregular periods, elevated FSH (follicle-stimulating hormone), or reduced fertility.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FXTAS_tremorataxia_syndrome_mainly_in_premutation-carrying_men\"><\/span><strong>FXTAS (tremor\/ataxia syndrome, mainly in premutation-carrying men)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>FXTAS mainly appears in premutation carriers aged 50 and older, and is characterized by progressive tremor (shaking of the hands), cerebellar ataxia, Parkinson&#8217;s-like symptoms, cognitive decline, and psychiatric symptoms. According to <a href=\"https:\/\/grj.umin.jp\/grj\/fmr1.htm\" target=\"_blank\" rel=\"noopener\">GeneReviews Japan<\/a>, penetrance among male carriers rises with age: about 17% in their 50s, 38% in their 60s, 47% in their 70s, and 75% at age 80 and older.<\/p>\n\n\n\n<p>In Japan, these fragile X-associated disorders \u2014 including FXTAS and FXPOI \u2014 can also qualify for public medical-expense assistance under <a href=\"https:\/\/www.nanbyou.or.jp\/entry\/4616\" target=\"_blank\" rel=\"noopener\">Designated Intractable Disease 205<\/a>. If you or a family member learns you carry a premutation, it&#8217;s worth discussing future life planning and fertility with a genetic counselor sooner rather than later, simply for peace of mind.<\/p>\n\n\n\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"6_Diagnosis_%E2%80%94_Confirmed_Through_FMR1_Genetic_Testing\"><\/span><strong>6. Diagnosis \u2014 Confirmed Through FMR1 Genetic Testing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Fragile X syndrome is definitively diagnosed with an FMR1 genetic test on a blood sample, which measures both the CGG repeat count and the methylation status.<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_diagnostic_path_after_birth\"><\/span><strong>The diagnostic path after birth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Screening based on clinical findings:<\/strong> Delayed language development, characteristic facial features, or behavioral traits can prompt a referral for genetic testing.<\/li>\n\n\n\n<li>PCR and Southern blot analysis: These blood tests measure the CGG repeat count and methylation status to distinguish between normal, premutation, and full mutation.<\/li>\n\n\n\n<li>Based on the results, genetic counseling with a clinical genetics specialist is arranged as needed.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Diagnosis_before_birth_prenatal_diagnosis\"><\/span><strong>Diagnosis before birth (prenatal diagnosis)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>According to <a href=\"https:\/\/grj.umin.jp\/grj\/fmr1.htm\" target=\"_blank\" rel=\"noopener\">GeneReviews Japan<\/a>, a definitive prenatal diagnosis of fragile X syndrome can be made by analyzing the FMR1 gene in cells obtained through chorionic villus sampling at around 10\u201312 weeks of pregnancy, or amniocentesis at around 15\u201318 weeks. Because these procedures carry some risk to the mother and fetus, the decision to proceed is generally made after genetic counseling.<\/p>\n\n\n\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"7_Can_NIPT_Detect_Fragile_X_Syndrome\"><\/span><strong>7. Can NIPT Detect Fragile X Syndrome?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Neither basic <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> nor expanded <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> (which also screens for microdeletions) covers fragile X syndrome. A definitive diagnosis requires an FMR1 genetic test performed on samples from chorionic villus sampling or amniocentesis.<\/strong><\/p>\n\n\n\n<p><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> looks for numerical changes in <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/chromosomal-abnormality\/?lang=en\">chromosomes<\/a>, such as trisomy 21, 18, or 13, and \u2014 on expanded plans \u2014 deletions or duplications (copy-number changes) in specific regions. Fragile X syndrome, by contrast, is caused by a repeat sequence of CGG that &#8220;lengthens,&#8221; which is neither a numerical abnormality nor a copy-number change. Because the underlying mechanism is completely different, it falls outside what current <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> technology can, in principle, detect.<\/p>\n\n\n\n<figure class=\"wp-table-block\"><table><thead><tr><th>Test<\/th><th>What it looks for<\/th><th>Coverage for fragile X syndrome<\/th><\/tr><\/thead><tbody><tr><td>Basic <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a><\/td><td>Mainly numerical changes in chromosomes, such as trisomy 21, 18, and 13<\/td><td>Not covered<\/td><\/tr><tr><td>Expanded <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> (microdeletion screening)<\/td><td>Deletions\/duplications (copy-number changes) in specific regions<\/td><td>Not covered (CGG repeat expansion is detected through a different mechanism)<\/td><\/tr><tr><td>Definitive testing (chorionic villus sampling or amniocentesis + FMR1 analysis)<\/td><td>CGG repeat count and methylation status of the FMR1 gene<\/td><td>Can provide a definitive diagnosis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>We also hear from people who ask, &#8220;Could a blood test around the time of conception tell me whether I&#8217;m a carrier?&#8221; That question falls under a separate test category called carrier screening, rather than <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a>. Which genes are covered varies by provider and plan, so please confirm directly with the testing company whether FMR1 is included.<\/p>\n\n\n\n<p>Guidelines from the Japan Society of Obstetrics and Gynecology also position <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> strictly as a non-definitive screening test. If you have a family history of fragile X syndrome or unexplained intellectual disability and are concerned about genetic risk, we recommend discussing it separately with a genetic counselor, apart from <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a>.<\/p>\n\n\n\n<p>If you&#8217;re not sure which testing plan fits your situation, try our <strong><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/plan-finder\/?lang=en\">Plan Finder<\/a><\/strong> tool. For more on the general testing window for <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a>, see our article on <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/nipt-until-when\/\">how late in pregnancy NIPT can be performed<\/a> (Japanese).<\/p>\n\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-16018d1d wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/line-registration\/?lang=en\" target=\"_blank\" rel=\"noopener\">Free Consultation via LINE<\/a><\/div>\n<\/div>\n\n\n\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"8_Treatment_and_Support_%E2%80%94_Managing_Symptoms_with_a_Multidisciplinary_Team\"><\/span><strong>8. Treatment and Support \u2014 Managing Symptoms with a Multidisciplinary Team<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>There is currently no treatment that reverses the CGG repeat expansion itself, but combining symptom-targeted medication with multidisciplinary developmental support can help build day-to-day skills over time.<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Symptom-targeted medication:<\/strong> Stimulant or non-stimulant medications for <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/adhd-genetics-symptoms-support\/\">ADHD<\/a>-like traits, and anti-epileptic drugs for seizures, among others.<\/li>\n\n\n\n<li><strong>Therapy, education, and rehabilitation:<\/strong> Speech therapy, behavioral therapy, occupational therapy, and special education are combined into a multi-pronged approach.<\/li>\n\n\n\n<li><strong>Sensory accommodations:<\/strong> Adjusting the environment for sensitivity to sound or touch can reduce day-to-day strain.<\/li>\n\n\n\n<li><strong>Genetic counseling for the family:<\/strong> Providing information and psychological support to family members who may themselves be carriers.<\/li>\n<\/ul>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-large\"><img decoding=\"async\" width=\"1024\" height=\"683\" src=\"\/nipt\/wp-content\/uploads\/2025\/07\/32362520_m-1024x683.jpg\" alt=\"Doctor\" class=\"wp-image-106255\"\/><\/figure><\/div>\n\n\n<p>A large clinical trial once tested a molecularly targeted drug, mavoglurant (AFQ056), aimed at an overactive neural signaling pathway (mGluR5) that results from FMRP loss. It showed no clear benefit over placebo, and development was discontinued. Research is now continuing into other neurotransmitter targets, including the GABA system, along with studies evaluating the real-world effectiveness of early, multidisciplinary intervention programs.<\/p>\n\n\n\n<p>In Japan, a research project aimed at establishing diagnostic and treatment systems for fragile X syndrome and related disorders in the Japanese population is registered with the <a href=\"https:\/\/mhlw-grants.niph.go.jp\/project\/18434\" target=\"_blank\" rel=\"noopener\">MHLW Grants System database<\/a>, so the infrastructure for diagnosis and support continues to steadily develop. In clinic conversations with families, we sometimes hear, &#8220;Getting a diagnosis actually made it clearer where to turn for support.&#8221; Because the combination and severity of symptoms differ from child to child, a support plan is best built together with a pediatrician, clinical genetics specialist, and developmental-support staff.<\/p>\n\n\n\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"9_Medical-Expense_Assistance_Programs_and_Where_to_Seek_Support\"><\/span><strong>9. Medical-Expense Assistance Programs and Where to Seek Support<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Fragile X syndrome can qualify for public medical-expense assistance in several ways: as Designated Intractable Disease 206 in adulthood, as Designated Intractable Disease 205 for premutation-related disorders such as FXTAS and FXPOI, and as a pediatric chronic specific disease for those under 18.<\/strong><\/p>\n\n\n\n<p>According to the <a href=\"https:\/\/www.shouman.jp\/disease\/html\/detail\/11_10_027.html\" target=\"_blank\" rel=\"noopener\">Center for Pediatric Chronic Disease Information<\/a>, fragile X syndrome is registered as Notification Number 34 within the &#8220;neuromuscular disease group.&#8221; Those under 18 (or under 20 if treatment must continue) can apply for medical-expense assistance through their municipal government office. From adulthood onward, assistance is available under <a href=\"https:\/\/www.nanbyou.or.jp\/entry\/4613\" target=\"_blank\" rel=\"noopener\">Designated Intractable Disease 206<\/a>, or, for premutation-related disorders, under <a href=\"https:\/\/www.nanbyou.or.jp\/entry\/4616\" target=\"_blank\" rel=\"noopener\">Designated Intractable Disease 205<\/a> (both have certification criteria based on severity and other factors).<\/p>\n\n\n\n<p>For details on the program and where to apply, please check with your local municipal office, or ask your treating physician or a medical social worker. Families don&#8217;t often meet others managing the same condition nearby, but connecting with patient and family associations can be a valuable source of information and emotional support.<\/p>\n\n\n\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Summary\"><\/span><strong>Summary<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Fragile X syndrome is caused by a <strong>full mutation \u2014 a CGG repeat in the FMR1 gene expanding past 200 copies<\/strong> \u2014 and is one of the most common single-gene causes of inherited intellectual disability.<\/li>\n\n\n\n<li>CGG repeat counts are classified as normal (50 or fewer), premutation (50\u2013200), or full mutation (over 200); premutation carriers can go on to develop separate conditions, FXPOI and FXTAS.<\/li>\n\n\n\n<li>Inheritance is X-linked dominant, and premutations inherited from the mother carry a higher expansion risk. A father&#8217;s premutation is never passed to sons but is always passed to daughters.<\/li>\n\n\n\n<li>Diagnosis is confirmed with an FMR1 genetic blood test; prenatally, a definitive diagnosis is possible via chorionic villus sampling or amniocentesis.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> (basic or expanded) does not cover fragile X syndrome, because CGG repeat expansion is detected through a different mechanism \u2014 an FMR1 genetic test is required for a definitive diagnosis.<\/li>\n\n\n\n<li>There is no cure yet, but multidisciplinary symptom management and developmental support can be combined with medical-expense assistance programs (Designated Intractable Disease 206\/205, or pediatric chronic disease assistance).<\/li>\n<\/ul>\n\n\n\n<p>If you&#8217;re interested in related conditions and tests, these articles may also help.<\/p>\n\n\n\n    <a href=\"\/nipt\/nipt-autism-developmental-disorders-detection\/\" class=\"blog-card\">\n      <div class=\"blog-card-content\">\n          <div class=\"blog-card-title\">NIPT\u3067\u767a\u9054\u969c\u5bb3\u30fb\u81ea\u9589\u75c7\u306f\u308f\u304b\u308b\uff1f\u691c\u67fb\u306e\u9650\u754c\u3068\u907a\u4f1d\u306e\u771f\u5b9f <\/div>\n          <div class=\"blog-card-excerpt\">NIPT\u3067\u81ea\u9589\u30b9\u30da\u30af\u30c8\u30e9\u30e0\u75c7\uff08ASD\uff09\u3084ADHD\u306a\u3069\u306e\u767a\u9054\u969c\u5bb3\u306f\u8a3a\u65ad\u3067\u304d\u308b\u306e\u304b\uff1f\u691c\u67fb\u3067\u5224\u660e\u3059\u308b\u300c\u67d3\u8272\u4f53\u8d77\u56e0\u306e\u77e5\u7684\u969c\u5bb3\u300d\u3068\u306e\u6c7a\u5b9a\u7684\u306a\u9055\u3044\u3001\u30c0\u30a6...<\/div>\n      <\/div>\n    <\/a>\n\n\n\n    <a href=\"\/nipt\/nipt-intellectual-disability-statistics-probability\/\" class=\"blog-card\">\n      <div class=\"blog-card-content\">\n          <div class=\"blog-card-title\">\u6570\u5b57\u3067\u898b\u308bNIPT\u3002\u77e5\u7684\u969c\u5bb3\u306e\u78ba\u7387\u30fb\u7684\u4e2d\u7387\u30fb\u9650\u754c <\/div>\n          <div class=\"blog-card-excerpt\">NIPT\u3067\u77e5\u7684\u969c\u5bb3\u304c\u5224\u660e\u3059\u308b\u78ba\u7387\u306f\u3069\u306e\u304f\u3089\u3044\u304b\uff1f35\u6b73\u300140\u6b73\u3068\u3044\u3063\u305f\u5e74\u9f62\u5225\u306e\u67d3\u8272\u4f53\u75be\u60a3\u767a\u751f\u7387\u3001\u691c\u67fb\u306e\u300c\u967d\u6027\u7684\u4e2d\u7387\u300d\u306e\u30ab\u30e9\u30af\u30ea\u3001\u305d\u3057\u3066\u77e5\u7684\u969c...<\/div>\n      <\/div>\n    <\/a>\n\n\n\n<p>If you&#8217;re concerned about your family&#8217;s genetic risk, or want to know exactly what <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> can and can&#8217;t tell you, try our <strong><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/plan-finder\/?lang=en\">Plan Finder<\/a><\/strong> tool. We also welcome phone inquiries (Japanese-language line): <a href=\"tel:0120169629\">0120-169-629<\/a>.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-16018d1d wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/mypage-nipt-reservation.hiro-clinic.or.jp\/registration\" target=\"_blank\" rel=\"noopener\">Book Your NIPT Appointment<\/a><\/div>\n\n\n\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/plan-finder\/?lang=en\" target=\"_blank\" rel=\"noopener\">Find the Right Test with Our Plan Finder<\/a><\/div>\n<\/div>\n\n\n\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Can_NIPT_detect_fragile_X_syndrome\"><\/span>Can NIPT detect fragile X syndrome?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>No \u2014 neither basic <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> nor expanded <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> (microdeletion screening) covers it. The CGG repeat expansion that causes fragile X syndrome works through a different mechanism than numerical chromosomal abnormalities or copy-number changes. A definitive diagnosis requires an FMR1 genetic test via chorionic villus sampling or amniocentesis.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_does_the_CGG_repeat_count_relate_to_the_disease\"><\/span>How does the CGG repeat count relate to the disease?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>According to the Center for Intractable Disease Information, a CGG repeat count of 50 or fewer is normal, 50\u2013200 is a premutation (within the fragile X-associated disorders range), and over 200 is a full mutation causing fragile X syndrome. Premutation carriers often show no symptoms themselves, but the repeat can expand to a full mutation in the next generation.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_effects_can_female_carriers_experience\"><\/span>What effects can female carriers experience?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Women who carry a premutation are reported to develop FXPOI (primary ovarian insufficiency) at a rate of about 21%, compared with about 1% in the general population, which can appear as irregular periods or reduced fertility. Men who carry a premutation, in particular, can also develop FXTAS (tremor\/ataxia syndrome), whose incidence rises with age from the 50s onward.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Will_it_be_passed_on_to_my_next_child\"><\/span>Will it be passed on to my next child?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Because inheritance is X-linked dominant, the risk differs depending on whether the premutation comes from the father or the mother. If the mother is a premutation carrier, a larger repeat count means a higher risk of expansion to a full mutation. A father&#8217;s premutation is always passed to daughters but never to sons. For details specific to your situation, please consult a genetic counselor.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Is_it_related_to_autism_spectrum_disorder\"><\/span>Is it related to autism spectrum disorder?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A relatively high proportion of males with fragile X syndrome are reported to meet the diagnostic criteria for autism spectrum disorder. That said, it does not apply to everyone, and how behavioral traits present varies from person to person.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Are_there_medical-expense_assistance_programs\"><\/span>Are there medical-expense assistance programs?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Those under 18 may qualify for pediatric chronic specific disease assistance (Notification Number 34); in adulthood, Designated Intractable Disease 206 (fragile X syndrome) or Designated Intractable Disease 205 (fragile X-associated disorders) may apply, subject to certification criteria. Applications are handled through your local municipal office.<\/p>\n\n\n\n<p><strong>Medical supervision: Dr. Hiroshi Oka<\/strong> \u2014 Director-in-Chief and Lab Director, Hiro Clinic (Fukumikai Medical Corporation). A graduate of Keio University School of Medicine, Dr. Oka holds a Ph.D. in Medicine and has passed the national medical licensing examinations of both Japan and the United States. He is one of the few physicians in Japan to hold laboratory director credentials. This article was prepared in line with Japan&#8217;s medical advertising guidelines, drawing on public and academic sources including Japan&#8217;s Center for Intractable Disease Information, the Center for Pediatric Chronic Disease Information, GeneReviews Japan, the MSD Manual Professional Version, and the MHLW Grants System database. Reported frequencies and figures vary somewhat between sources; please consult your physician for decisions about diagnosis and treatment.<\/p>\n\n\n<script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Can NIPT detect fragile X syndrome?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"No \u2014 neither basic NIPT nor expanded NIPT (microdeletion screening) covers it. The CGG repeat expansion that causes fragile X syndrome works through a different mechanism than numerical chromosomal abnormalities or copy-number changes. A definitive diagnosis requires an FMR1 genetic test via chorionic villus sampling or amniocentesis.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How does the CGG repeat count relate to the disease?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"According to the Center for Intractable Disease Information, a CGG repeat count of 50 or fewer is normal, 50\u2013200 is a premutation (within the fragile X-associated disorders range), and over 200 is a full mutation causing fragile X syndrome. Premutation carriers often show no symptoms themselves, but the repeat can expand to a full mutation in the next generation.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What effects can female carriers experience?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Women who carry a premutation are reported to develop FXPOI (primary ovarian insufficiency) at a rate of about 21%, compared with about 1% in the general population, which can appear as irregular periods or reduced fertility. Men who carry a premutation, in particular, can also develop FXTAS (tremor\/ataxia syndrome), whose incidence rises with age from the 50s onward.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Will it be passed on to my next child?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Because inheritance is X-linked dominant, the risk differs depending on whether the premutation comes from the father or the mother. If the mother is a premutation carrier, a larger repeat count means a higher risk of expansion to a full mutation. A father's premutation is always passed to daughters but never to sons. For details specific to your situation, please consult a genetic counselor.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is it related to autism spectrum disorder?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"A relatively high proportion of males with fragile X syndrome are reported to meet the diagnostic criteria for autism spectrum disorder. That said, it does not apply to everyone, and how behavioral traits present varies from person to person.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Are there medical-expense assistance programs?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Those under 18 may qualify for pediatric chronic specific disease assistance (Notification Number 34); in adulthood, Designated Intractable Disease 206 (fragile X syndrome) or Designated Intractable Disease 205 (fragile X-associated disorders) may apply, subject to certification criteria. Applications are handled through your local municipal office.\"\n      }\n    }\n  ]\n}\n<\/script>\n","protected":false},"excerpt":{"rendered":"Here is the short an&#8230;\n <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/fragile-x-syndrome-guide\/?lang=en\">\u7d9a\u304d\u3092\u8aad\u3080<\/a>","protected":false},"author":122,"featured_media":106246,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[97],"tags":[],"class_list":["post-111984","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/posts\/111984","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/users\/122"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/comments?post=111984"}],"version-history":[{"count":3,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/posts\/111984\/revisions"}],"predecessor-version":[{"id":133703,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/posts\/111984\/revisions\/133703"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/media\/106246"}],"wp:attachment":[{"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/media?parent=111984"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/categories?post=111984"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/tags?post=111984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}